Page 38 - Hawkary2017

Sun Pharma

We were pioneers among Indian pharmaceutical companies to see
tremendous value in investing in research & development (R&D). Our
early investments in R&D, beginning three decades ago, enabled us to
make technology our key differentiator and develop a basket of robust
products for diverse markets across the world. Our core strength lies in
our ability to excel in developing generics and technologically complex
products through focused teams in formulations, process chemistry and
analytical development. We have the capability to deliver quality products
within established timelines, at low costs and without compromising on
quality.

We have around 2000 research scientists working in multiple R&D
centres equipped with cutting-edge enabling technologies for research.
Our scientists have expertise in developing generics, difficult to make
technology intensive products, Active Pharmaceutical Ingredients (APIs),
Novel Drug Delivery Systems (NDDS) and New Chemical Entities (NCEs).

Our capabilities span the development of differentiated products, such
as liposomal products, inhalers, lyophilised injections, nasal sprays,
besides developing controlled release dosage forms.
Over the years, we have developed expertise and gathered experience in
performing pharmacokinetic and bioequivalence studies to facilitate the
introduction of generic or branded generic drugs into the international
market. Our 408-bed clinical pharmacology unit with expert staff works
on bioequivalence/bioavailability studies in compliance with GCP.
Facilities include a full-fledged site for Phase I clinical studies. Our CPU
has been audited by US FDA, ANVISA, MHRA, and DCGI among others.